SRNE - ソレント・セラピュ―ティクス （Sorrento Therapeutics Inc.）

In the last trading session, 5.56 million shares of the Sorrento Therapeutics Inc. (NASDAQ:SRNE) were traded, and its beta was 2.23. Most recently the company’s share price was $2.60, and it changed around -$0.02 or -0.76% from the last close, which brings the market valuation of the company to $1.03B. SRNE currently trades at a … Sorrento Therapeutics Inc. (NASDAQ: SRNE) Could See A Rise In Prices Shortly. Read More »

https://www.investing.com/news/pro/increasing-unusual-put-option-volume-tip-clvs-ten-tsm-mxea-dm-srne-432SI-2859546

This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated July 28, 2022. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here . Source: Shutterstock Growing up, my family’s hamburger grilling looked like this. Ground beef? Check. Salt, pepper and spices? Of course. Then add bell peppers, onions, saltine crackers and an egg for good measure? Umm… That too. It was only after the internet came around did I learn we weren’t supposed to turn our burger patties into wads of meatloaf. Many of the world’s top chefs create award-winning concoctions with only three ingredients: ground beef, salt and pepper. The amateur practice of overdoing things extends to investing too. There’s always a temptation to have 30… 50… 100 open positions to avoid the feeling of missing out. And rather than shine, these gargantuan portfolios eventually look like a bland mishmash of uninspiring ingredients. Getting Rich Without Really Trying The secret to winning portfolios, of course, is to concentrate bets in a handful of high-conviction positions.

The FDA has signed off Sorrento Therapeutics Inc''s (NASDAQ: SRNE ) Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function. The Phase 1 study will examine the PK in patients with moderate renal and hepatic impairment. Using a cross-over design, two doses of STI-1558 (300 mg and 600 … Full story available on Benzinga.com

San Diego, California-based biotech Sorrento Therapeutics (SRNE) traded higher on Tuesday after the company announced that the U.S

Sorrento Therapeutics (NASDAQ:SRNE) and Alector (NASDAQ:ALEC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability. Profitability This table compares Sorrento Therapeutics and Alectors net margins, return on equity and return on assets. []

Wall Street brokerages expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report $10.21 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Sorrento Therapeutics earnings. The lowest sales estimate is $3.51 million and the highest is $16.90 million. Sorrento Therapeutics reported sales of $11.75 million in the same quarter []

The trading price of Sorrento Therapeutics Inc. (NASDAQ:SRNE) closed lower on Tuesday, November 02, closing at $6.95, -1.42% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee''s Pharmaceutical Holdings Limited (Lee''s Pharma, HKEX: 950) has submitted a NDA (new drug application) for the anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory to treat recurrent or metastatic cervical cancer. The NDA application has been accepted by China NMPA.

Equities research analysts expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report earnings of ($0.21) per share for the current quarter, according to Zacks. Two analysts have made estimates for Sorrento Therapeutics earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.17). Sorrento Therapeutics posted earnings per share of []

Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico. Sorrento''s Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units. Sorrento Therapeutics Mexico will coordinate all activities required for commercialization of COVI-STIX, and for the clinical trials and registration of Sorrento''s portfolio of products for the Mexican and potentially other Latin American Markets. SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE , ", Sorrento", )) today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico ("Sorrento Mexico"), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories. Sorrento Mexico has established offices in Mexico City with Dr.

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (Sorrento Mexico), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.

PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced complete enrollment of SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica. SP-102 has received Fast Track status from the FDA.